Kevin Byrnes - MEDIFAST INC Independent Director
| MED Stock | USD 32.44 0.03 0.09% |
Director
Mr. Kevin G. Byrnes serves as Independent Director of Medifast, Inc. since May 23, 2013. Mr. Byrnes has more than 40 years of financial experience working in the retail and commercial banking industries. He was the Chairman of the Board of Bay Bank, with assets of approximately 500 million and 12 branches located in the Baltimore metropolitan area, from 2010 to 2015. Mr. Byrnes served as PresidentCOO and Director of Provident Bank from 2002 to 2009. Provident, acquired by MT Bank in May 2009, was the largest independent financial institution in the Maryland and Northern Virginia marketplaces at that time, with 6.5 billion in assets, 150 branches and 1, 600 employees. Prior to serving at Provident Bank, Mr. Byrnes spent 25 years with the Chase Manhattan Bank in various executive management positions. Mr. Byrnes began his career at Bankers Trust Co. in New York. Mr. Byrnes received a BBA from Pace University since 2013.
| Age | 73 |
| Tenure | 11 years |
| Address | 100 International Drive, Baltimore, MD, United States, 21202 |
| Phone | 410 581 8042 |
| Web | https://medifastinc.com |
MEDIFAST INC Management Efficiency
The company has Return on Asset of 0.2524 % which means that on every $100 spent on assets, it made $0.2524 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.5577 %, implying that it generated $0.5577 on every 100 dollars invested. MEDIFAST INC's management efficiency ratios could be used to measure how well MEDIFAST INC manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.34. The current year's Return On Capital Employed is expected to grow to 0.61. At present, MEDIFAST INC's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 15.4 M, whereas Net Tangible Assets are forecasted to decline to about 125 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Paul Fribourg | Estee Lauder Companies | 66 | |
| Daniel Heinrich | Edgewell Personal Care | 64 | |
| Robert Steele | Newell Brands | 62 | |
| Swan Sit | Edgewell Personal Care | 43 | |
| Rose Bravo | Estee Lauder Companies | 69 | |
| Brett Icahn | Newell Brands | 37 | |
| James Johnson | Edgewell Personal Care | 68 | |
| Yuwen Chen | Yatsen Holding | 38 | |
| Axel Marot | Inter Parfums | 42 | |
| Scott Cowen | Newell Brands | 70 | |
| Daniel Gonzaga | Natura Co Holding | N/A | |
| Maureen Watson | ELF Beauty | 52 | |
| Courtney Mather | Newell Brands | 41 | |
| Debra Crew | Newell Brands | 47 | |
| Gerardo Lopez | Newell Brands | 58 | |
| Charlene Barshefsky | Estee Lauder Companies | 70 | |
| James Craigie | Newell Brands | 64 | |
| Robert BensoussanTorres | Inter Parfums | 60 | |
| Elizabeth Long | Edgewell Personal Care | 67 | |
| Aerin Lauder | Estee Lauder Companies | 44 | |
| Steven Strobel | Newell Brands | 59 | |
Management Performance
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.25 |
MEDIFAST INC Leadership Team
Elected by the shareholders, the MEDIFAST INC's board of directors comprises two types of representatives: MEDIFAST INC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEDIFAST. The board's role is to monitor MEDIFAST INC's management team and ensure that shareholders' interests are well served. MEDIFAST INC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEDIFAST INC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Margaret Sheetz, President COO, Director | ||
| Ming Xian, Independent Director | ||
| Brian Kagen, Chief Marketing Officer and Executive VP | ||
| Anthony Tyree, Chief Marketing Officer | ||
| Michael Hoer, Independent Director | ||
| Timothy Robinson, Chief Financial Officer | ||
| Jeffrey Brown, Lead Independent Director | ||
| Fran Lawler, Chief Human Resource Officer | ||
| Lauren Walker, Executive Vice President - Supply Chain Operations | ||
| Glenn Welling, Independent Director | ||
| Jason Esq, General VP | ||
| Jason Groves, Executive Vice President, General Counsel, Corporate Secretary | ||
| Joseph Kelleman, Interim Chief Financial Officer, Vice President - Finance | ||
| Charles Connolly, Independent Director | ||
| James Maloney, Chief Financial Officer, Interim Principal Accounting Officer | ||
| Tony Tyree, Chief Marketing Officer | ||
| Donald Gould, Executive VP of Information Technology | ||
| Michael MacDonald, Chairman, CEO and Chairman of Executive Committee | ||
| Jeanne City, Executive Vice President - Human Resources | ||
| Jonathan Mackenzie, Chief Accounting Officer | ||
| Daniel Chard, Executive Chairman of the Board, Chief Executive Officer | ||
| James CPA, Chief Officer | ||
| Mehrnaz Ameli, President - Take Shape For Life | ||
| Bill Baker, Executive Vice President Information Technology | ||
| William Baker, Executive Vice President Information Technology | ||
| Stephen Johnson, Chief Accounting Officer, Vice President - Finance | ||
| Andrea Thomas, Independent Director | ||
| Steven Zenker, Vice Relations | ||
| Scott Schlackman, Independent Director | ||
| Kevin Byrnes, Independent Director | ||
| Carl Sassano, Independent Director | ||
| Constance Hallquist, Independent Director | ||
| Nicholas Johnson, Executive Vice President - Coach Success, Market President of OPTAVIA USA | ||
| Claudia Greninger, Executive Vice President - Human Resources |
MEDIFAST Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEDIFAST INC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.25 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 222.05 M | ||||
| Shares Outstanding | 10.9 M | ||||
| Shares Owned By Insiders | 2.70 % | ||||
| Shares Owned By Institutions | 97.73 % | ||||
| Number Of Shares Shorted | 2.66 M | ||||
| Price To Earning | 13.99 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEDIFAST INC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade MEDIFAST Stock refer to our How to Trade MEDIFAST Stock guide.Note that the MEDIFAST INC information on this page should be used as a complementary analysis to other MEDIFAST INC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for MEDIFAST Stock analysis
When running MEDIFAST INC's price analysis, check to measure MEDIFAST INC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEDIFAST INC is operating at the current time. Most of MEDIFAST INC's value examination focuses on studying past and present price action to predict the probability of MEDIFAST INC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEDIFAST INC's price. Additionally, you may evaluate how the addition of MEDIFAST INC to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is MEDIFAST INC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MEDIFAST INC. If investors know MEDIFAST will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MEDIFAST INC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Dividend Share 4.95 | Earnings Share 9.1 | Revenue Per Share 98.498 | Quarterly Revenue Growth (0.43) |
The market value of MEDIFAST INC is measured differently than its book value, which is the value of MEDIFAST that is recorded on the company's balance sheet. Investors also form their own opinion of MEDIFAST INC's value that differs from its market value or its book value, called intrinsic value, which is MEDIFAST INC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MEDIFAST INC's market value can be influenced by many factors that don't directly affect MEDIFAST INC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MEDIFAST INC's value and its price as these two are different measures arrived at by different means. Investors typically determine if MEDIFAST INC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MEDIFAST INC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.